stroke
Conditions
Interventions
Experimental group:sancai acupuncture+Western medicine treatment
Sponsors
China Aerospace Science and Industry Corporation 731 Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age: Adult patients aged 18 and above. 2. Ischemic stroke: Patients diagnosed with acute ischemic stroke based on clinical manifestations and imaging examinations (head CT or MRI) according to the diagnostic criteria of the American Heart Association/American Stroke Association (AHA/ASA) or the European Stroke Organization (ESO) guidelines. Imaging examination should clearly show cerebral artery occlusion or significant stenosis and there should be no signs of bleeding. 3. Hemorrhagic stroke: Patients diagnosed with intracerebral hemorrhage or subarachnoid hemorrhage through head CT or MRI imaging according to the diagnostic criteria of the American Heart Association/American Stroke Association (AHA/ASA) or the European Stroke Organization (ESO) guidelines. Imaging should show signs of intracranial hematoma or subarachnoid hemorrhage and exclude bleeding caused by other non stroke reasons. 4. Time of onset: Within 24 hours of onset (acute phase patients) and both first-time and recurrent stroke events can be included. 5. One of the following clinical manifestations: Patients need to show obvious focal neurological deficits such as unilateral limb weakness or paralysis (hemiplegia) facial paralysis sensory loss aphasia visual impairment etc. and these symptoms are related to stroke. 6. Informed consent: The patient or legal representative should voluntarily participate in the study with full knowledge and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Non stroke neutral brain injury: Exclude all patients with brain injury caused by non stroke neutral reasons such as traumatic intracranial hemorrhage hemorrhagic lesions caused by brain tumors or cerebral infarction. The etiology of these patients is different from that of stroke which may affect the interpretation of research results. 2. Severe heart disease: Exclude all patients with severe heart disease such as acute myocardial infarction end-stage heart failure or severe arrhythmia. The cardiac condition of these patients may lead to intolerance to stroke treatment affecting prognosis. 3. Merge other neurological diseases: Exclude patients with other diseases that affect neurological function evaluation such as Parkinson's disease Alzheimer's disease or epilepsy. These diseases may interfere with the neurological function assessment of stroke and affect the accuracy of research data. 4. Coagulation dysfunction: For patients with hemorrhagic stroke if the patient has severe coagulation dysfunction (such as congenital hemorrhagic disease) and cannot suspend anticoagulant therapy they will be excluded. Abnormal coagulation function in these patients may increase the risk of treatment and affect the prognosis of hemorrhagic stroke. 5. Pregnant or lactating women: Pregnant or lactating women are excluded due to potential side effects on the fetus or infant caused by medication or other interventions that may be involved in stroke treatment. 6. Severe liver and kidney dysfunction: Patients with severe liver or kidney disease (such as end-stage renal disease or cirrhosis) should be excluded. The metabolic and excretory functions of these patients are impaired which may affect drug metabolism and lead to distorted evaluation of treatment efficacy and adverse reactions. 7. Patients with poor treatment compliance or inability to complete follow-up: Exclude patients who are expected to be unable to complete the study plan or long-term follow-up ensuring the integrity of study data and the effectiveness of follow-up. 8. Other serious systemic diseases: such as advanced malignant tumors or patients with severe systemic infections. These systemic diseases may interfere with the evaluation of stroke treatment efficacy and may have a decisive impact on patient prognosis thereby interfering with research conclusions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neuromotor function;Speech Function; | — |
Secondary
| Measure | Time frame |
|---|---|
| case fatality rate;Swallowing function;anxiety; | — |
Countries
China
Contacts
Public Contactzahngyang
China Aerospace Science and Industry Corporation 731 Hospital
Outcome results
None listed